SCHEMBL3459540

SCHEMBL3459540

C1CSC(NC2CCCS2)C1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13137791 0.77
SCHEMBL9078520 0.77
SCHEMBL3914525 0.77
Hydrochloric Acid SCHEMBL11248175 0.75
SCHEMBL3637086 0.71
SCHEMBL29023661 0.71
SCHEMBL12219622 0.71
SCHEMBL12947548 0.71
SCHEMBL3637717 0.68
SCHEMBL14573016 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3328427-B1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION MASSACHUSETTS GEN HOSPITAL (US) 2024-05-29 EP disclosed
EP-3337917-B1 SELF-HEALING COATINGS FOR OIL AND GAS APPLICATIONS BAKER HUGHES HOLDINGS LLC (US) 2023-10-11 EP disclosed
US-20230303709-A1 Antibody Derivatives with Conditionally Enabled Effector Function THE GENERAL HOSPITAL CORPORATION 2023-09-28 US disclosed
US-11492503-B2 Self-healing coatings for oil and gas applications BAKER HUGHES, A GE COMPANY, LLC (US) 2022-11-08 US disclosed
US-11466093-B2 Antibody derivatives with conditionally enabled effector function THE GENERAL HOSPITAL CORPORATION (US) 2022-10-11 US disclosed
US-20180215831-A1 Antibody Derivatives with Conditionally Enabled Effector Function THE GENERAL HOSPITAL CORPORATION 2018-08-02 US disclosed
EP-3328427-A1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION The General Hospital Corporation (US) 2018-06-06 EP disclosed
EP-2046375-B1 METHODS AND COMPOSITIONS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING MASSACHUSETTS GEN HOSPITAL (US) 2017-04-05 EP disclosed
WO-2017019729-A1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION THE GENERAL HOSPITAL CORPORATION (US) 2017-02-02 WO disclosed
EP-2178559-B1 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS GEN HOSPITAL CORP (US) 2015-06-24 EP disclosed
US-8993295-B2 Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting THE GENERAL HOSPITAL CORPORATION (US) 2015-03-31 US disclosed
WO-2014031530-A1 INHIBITING CORROSION CAUSED BY AQUEOUS ALDEHYDE SOLUTIONS BAKER HUGHES INCORPORATED (US) 2014-02-27 WO disclosed
US-8524241-B2 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A THE GENERAL HOSPITAL CORPORATION (US) 2013-09-03 US disclosed
US-8420094-B2 2013-04-16 US disclosed
US-20100256070-A1 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS THE GENERAL HOSPITAL CORPORATION 2010-10-07 US disclosed
EP-2178559-A2 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS The General Hospital Corporation (US) 2010-04-28 EP disclosed
US-20100055761-A1 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING THE GENERAL HOSPITAL CORPORATION (US) 2010-03-04 US disclosed
EP-2046375-A2 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING The General Hospital Corporation (US) 2009-04-15 EP disclosed
WO-2009014650-A2 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS THE GENERAL HOSPITAL CORPORATION (US) 2009-01-29 WO disclosed
WO-2008011157-A2 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING THE GENERAL HOSPITAL CORPORATION (US) 2008-01-24 WO disclosed